Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 265-272

  Kim, Chong Kook ^a   Choi, Eun Jeong ^a   Choi, Sung Hee ^a   Park, Jeong Sook ^a   Haider, Khawaja Hasnain ^b   Ahn, Woong Shick ^c  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF THE PUNJAB   (Pakistan)

^c The Catholic University of Korea   (South Korea)

Author keywords

Cationic liposome; DDC; Ovarian cancer; p53

Indexed keywords

CHOLESTEROL; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DIOLEOYLTRIMETHYLAMINOPROPANE; GREEN FLUORESCENT PROTEIN; LIPOCORTIN 5; LIPOSOME; PHOSPHATIDYLETHANOLAMINE; PLASMID DNA; PLASMID VECTOR; PROTEIN P53; TRIMETHYLAMINE; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL BASED GENE THERAPY; CELL GROWTH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; GENE TRANSFER; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 0041622921     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00248-8     Document Type: Article

References (40)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1998. CA Cancer J Clin. 48:1998;6-29.
2. Bast R.C. Jr, Boyer C.M., Jacobs I., Xu F.J., Wu S., Wiener J., Kohler M., Berchuck A. Cell growth regulation in epithelial ovarian cancer. Cancer. 71:1993;1597-1601.
3. Milner B., Allan L., Eccles D., Kitchener H., Leonard R.C., Kelly K.F., Parkin D.E., Haites N.E. p53 mutation in a common genetic event in ovarian carcinoma. Cancer Res. 53:1993;2128-2132.
4. Porter P., Gown A., Kramp S., Coltrera M. Widespread p53 overexpression in human malignant tumors. Am J Pathol. 140:1992;145-153.
5. Bartek J., Bartkova J., Vojtesek B., Staskova Z., Lukas J., Rejthar A., Kovarik J., Midgley C.A., Gannon J.V., Lane D.P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 6:1991;1699-1703.
6. Havrilesky L, Berchuck A, Hamdan H, Walsh K, Leon J. Relationship between p53 mutation, p53 overexpression and survival in advanced ovarian cancers treated on Gynecologic Oncology Group Protocols 114 and 132. Soc Gynecol Oncol 30th Annual Meeting, San Francisco, CA, 1999.
7. Pirollo K.F., Xu L., Chang E.H. Non-viral gene delivery for p53. Curr Opin Molec Thrapeut. 2:2000;168-175.
8. Sidransky D., Hollstein M. Clinical implications of the p53 gene. Annu Rev Med. 47:1996;285-301.
9. Fujiwara T., Grimm E.A., Mukgopadhyay T., Cai D.W., Owen-Schaub L.B., Roth J.A. A retroviral wild type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 53:1993;4129-4133.
10. Shaw P., Bovey R., Tardy S., Sahli R., Sordat B., Costa J. Induction of apoptosis by wild type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci. 89:1992;4495-4499.
11. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., Hong W.K., Komaki R., Lee J.J., Nesbitt J.C., Pisters K.M.W., Putnam J.B., Schea R., Shin D.M.N., Xu K., Stephens L.C., McDonnell T.J., Mukhopadhyay Y., Cai D. Retrovirus-mediated wild type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 2:1996;985-991.
12. Ramesh R., Saeki T., Templeton N.S., Ji L., Stephens L.C., Ito I., Wilson D.R., Wu Z., Branch C.D., Minna J.D., Roth J.A. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther. 3:2001;337-350.
13. Zou Y., Zong G., Ling Y.H., Perez-Soler R. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther. 7:2000;683-696.
14. Whitmore M., Li S., Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6:1999;1867-1875.
15. Gao X., Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun. 179:1991;280-285.
16. Hortobagyi G.N., Ueno N.T., Xia W., Zhang S., Wolf J.K., Putnam J.B., Weiden P.L., Willey J.S., Carey M., Branham D.L., Payne J.Y., Tucker S.D., Bartholomeusz C., Kilbourn R.G., De Jager R.L., Sneige N., Katz R.L., Anklesaria P., Ibrahim N.K., Murray J.L., Theriault R.L., Valero V., Gershenson D.M., Bevers M.W., Huang L., Lopez-Berestein G., Hung M.C. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects a phase I clinical trial . J Clin Oncol. 19:2001;3422-3433.
17. Kim C.K., Haider KhH, Choi S.H., Choi E.J., Ahn W.S., Kim Y.B. Nonviral vector for efficient gene transfer to human ovarian adenocarcinoma cells. Gynecol Oncol. 84:2002;85-93.
18. Yaginuma Y., Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 52:1992;4196-4199.
19. Nchinda G., Uberla K., Zschornig O. Characterization of cationic lipid DNA transfection complexes differing in susceptability to serum inhibition. BMC Biotechnol. 2:2002;12.
20. Mbawuike I.N., Zhang Y., Wang Y., Song L. Cationic liposome-mediated enhanced generation of human HLA-restricted RSV-specific CD8+ CTL+. J Clin Immunol. 22:2002;164-175.
21. Wolf J.K., Mills G.B., Bazzet L., Bast R.C. Jr, Roth J.A., Gershenson D.M. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol. 75:1999;261-266.
22. Kageshita T., Mizuno M., Ono T., Matsumoto K., Saida T., Yoshida J. Growth inhibition of human malignant melanoma transfected with the human interferon-beta gene by means of cationic liposomes. Melanoma Res. 11:2001;337-342.
23. Felgner P.L., Tsai Y.J., Sukhu L., Wheeler C.J., Manthorpe M., Marshall J., Cheng S.H. Improved cationic lipid formulations for in vivo gene therapy. Ann NY Acad Sci. 771:1995;126-138.
24. Lewis J.G., Lin K., Kothavale A., Flanagan W.M., Matteucci M.D. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA. 93:1996;3176-3181.
25. Kim C.K., Haider K.H., Lim S.J. Gene medicine a new field of molecular medicine . Arch Pharm Res. 24:2001;1-15.
26. Nabel G.J., Nabel E.G., Yang Z.Y., Fox B.A., Plautz G.E., Gao X., Huang L., Shu S., Gordon D., Chang A.E. Direct gene transfer with DNA-liposome complexes in melanoma expression, biologic activity, and lack of toxicity in humans . Proc Natl Acad Sci USA. 90:1993;11307-11311.
27. Mountain A. Gene therapy the first decade . Trends Biotechnol. 18:2000;119-128.
28. Updated list of clinical protocols. Hum Gene Ther 1999;10:1043-92.
29. Lee M.J., Cho S.S., You J.R., Lee Y., Kang B.D., Choi J.S., Park J.W., Suh Y.L., Kim J.A., Kim D.K., Park J.S. Intraperitoneal gene delivery mediated by a novel cationic liposome in a peritoneal disseminated ovarian cancer model. Gene Ther. 9:2002;859-866.
30. Philip R., Clary B., Brunette E., Kilinski L., Murugesh D., Sorich M., Yau J., Lebkowski J., Lyerly H.K., Philip M. Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. Clin Cancer Res. 2:1996;59-68.
31. Xing X., Yujiao Chang J., Hung M. Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy. Adv Drug Deliv Rev. 30:1998;219-227.
32. Yu D., Matin A., Xia W., Sorgi F., Huang L., Hung M.C. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 11:1995;1383-1388.
33. Hofland H., Huang L. Inhibition of human ovarian carcinoma cell proliferation by liposome-plasmid DNA complex. Biochem Biophys Res Commun. 207:1995;492-496.
34. Tros de Ilarduya C., Arangoa M.A., Moreno-Aliaga M.J., Duzgunes N. Enhanced gene delivery in vitro and in vivo by improved transferrin-lipoplexes. Biochim Biophys Acta. 1561:2002;209-221.
35. Nabel E.G., Yang Z., Muller D., Chang A.E., Gao X., Huang L., Cho K.J., Nabel G.J. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum Gene Ther. 5:1994;1089-1094.
36. Recombinant DNA Advisory Committee (RAC) Committee Report: Human Gene Therapy Protocols, 1998.
37. Zou Y., Zong G., Ling Y.H., Hao M.M., Lozano G., Hong W.K., Perez-Soler R. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst. 90:1998;1130-1137.
38. Lesoon-Wood L.A., Kim W.H., Kleinman H.K., Weintraub B.D., Mixson A.J. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther. 6:1995;395-405.
39. Chen Q.R., Mixson A.J. Systemic gene therapy with p53 inhibits breast cancer recent advances and therapeutic implications . Front Biosci. 3:1998;D997-D1004.
40. Xu L., Pirollo K.F., Chang E.H. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release. 74:2001;115-128.